1 / 20

Carotid Disease

Carotid Disease. Core Surgical Trainees Vascular Teaching Day Kent and Canterbury Hospital 1st December 2009. J W B Senaratne, Cons Vasc Surgeon S J Matheiken, SpR Vasc Surgery. Why talk about it?. Stroke is the third leading cause of death

edmund
Télécharger la présentation

Carotid Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Carotid Disease Core Surgical Trainees Vascular Teaching Day Kent and Canterbury Hospital 1st December 2009 J W B Senaratne, Cons Vasc Surgeon S J Matheiken, SpR Vasc Surgery

  2. Why talk about it? • Stroke is the third leading cause of death • A third of patients who stroke will do so again within 5 years • Some strokes are preventable

  3. Why talk about it to you?

  4. And what should we talk about? • CEA • CAS • BMT

  5. UNMODIFIABLE Age Gender Previous CVA Family history CVA MODIFIABLE Smoking Blood Pressure Diabetes Mellitus Hyperlipidaemia Carotid stenosis Risk Factors for Stroke

  6. Relevant CEA trials • Joint study of extracranial arterial occlusion • NASCET • ECST • ACAS • ACST

  7. What should the patient know? • What are the benefits of having a carotid endarterectomy • What are the risks involved?

  8. Complications of CEA • Stroke / Mortality : 1 – 3 % • Cranial Nerve injury: • Haemorrhage • Restenosis • Paraesthesiae

  9. Indications for CEA • NNT to prevent major stroke/ death • At 5 years: • Medical group: 25% stroke / death • CEA group: 15% stroke / death • ARR: 10% • RR reduction: 40% • NNT: 10 • These numbers are for sympatomatic patients with critical stenosis of the ICA

  10. Incidentally detected asymptomatic ICA stenosis and you • ACAS: 3 year outcome 11% in medical group vs 5.1% in CEA : • NNT 17 with complication rate under 3%

  11. CETC findings • Symptomatic stenosis over 50% benefits from prompt intervention • Benefit is higher in severe disease 70-99% • Maximum benefit if intervention within 2-4 week of symptoms • No benefit for intervention beyond 12 weeks in 50-69% disease • No benefit for intervention beyond 4 weeksin women with 50-69% stenosis • No benefit for intervention inasymptomatic women

  12. Timing of CEA • Half the preventable strokes after a TIA or initial stroke occur within 7 days

  13. Rapid Access Carotid Endarterectomy

  14. Indications for CEA in EKHT • RACE • Acute symptoms wih stenosis 50 – 99% • TIA with ABCD2 score 4-6 • ASA 1 or 2 • Elective CEA • Symptomatic stenosis 50-99% • Stroke in prev 6/12, TIA, AmFugax, Tinnitus • Asymptomatic stenosis 60-99%, not F > 70y

  15. Carotid Stenting • Leicester, LEXINGTON, WALLSTENT • CAVATAS – UK/ Europe • EVA-3S - France • SPACE – Germany / Austria • ICSS – Europe • CREST – North America

  16. Outcomes of asymptomatic CAS trials • SPACE – no statistical difference 30-day • EVA-3S: stopped twice due to stroke rates • CAVATAS – comparable results but high restenosis • SAPPHIRE – comparable results, but interpretation bias, stopped early

  17. Conclusions from CAS evidence • High death / stroke rates for CAS in elderly (over 80 in CREST; over 75 in SPACE) • No evidence in favour of CAS in symptomatic patients not high risk for CEA; should be done as part of trial • CAS an acceptable alternative when pt high risk for CEA, especially recently symptomatic, male, <75y • No evidence that CAS has any benefit over BMT in the asymptomatic patient whether high risk or not for CEA and not recommended unless IAPR <4%.

  18. BMT • Lag-phase for effect • More important in asymptomatic group • Based on ACST BMT data, 1000 interventions at 30 day rate 2.8% would prevented only 53 strokes

  19. Things to clarify • Quantification of disease in trials • Reccos for asymptomatic disease; risk reductions • Incidence of other complications in CEA

  20. Take Home Messages • Symptomatic stenosis over 70%: must intervene as soon as safely possible • Symptomatic stenosis 50-69%: consider for intervention on individual basis • Asymptomatic stenosis: intervention on individual basis • CEA vs stenting: ongoing trials; CEA preferred in most settings; CAS acceptable in symptomatic stenosis in patient at high risk for CEA procedure.

More Related